United StatesThe FDA has raised concerns about Replimune's skin cancer treatment, RP1, stating that the company lacks sufficient data to justify approval. This is the third attempt by Replimune to gain regulatory clearance for its controversial drug. The FDA criticized the single-arm trial used by the company, which tested RP1 in combination with the PD-1 inhibitor Opdivo, arguing it does not adequately assess the drug's efficacy or systemic benefits. Replimune responded by asserting that conducting a randomized controlled trial would be unethical and impractical for patients who have already failed PD-1 therapy.
Bias read (Center): The article presents both the FDA's concerns and Replimune's counterarguments without overtly favoring either side. It reports on the scientific and regulatory debate without taking a clear ideological stance, maintaining a balanced presentation of the conflicting perspectives.
